“Diabetic Retinopathy Market” report has been added to DelveInsight
Diabetic Retinopathy Overview
Diabetic Retinopathy is a condition that occurs in people who have diabetes. It causes progressive damage to the retina, the light-sensitive lining at the back of the eye. It is a major cause of vision impairment and blindness among working-age adults. Diabetic retinopathy is classified into two types, Non-proliferative diabetic retinopathy (NPDR) and Proliferative diabetic retinopathy (PDR). NPDR is the early stage of the disease in which symptoms.
Diabetic Retinopathy Market
DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Diabetic Retinopathy Market: Report
The Diabetic Retinopathy (DR) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Diabetic Retinopathy (DR) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Diabetic Retinopathy (DR) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Request free sample copy- https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
Diabetic Retinopathy Market: Geography Covered
Diabetic Retinopathy Market: Treatment
The treatment of Diabetic Retinopathy depends on the type and severity of the disease. The treatment is mainly focused on the slowing or stopping progression of the condition. Once DR has been diagnosed, ophthalmological treatment with laser photocoagulation is especially directed to treat two key complications: retinal neovascularization and severe or clinically significant macular edema.
In May 2019, the US FDA approved Aflibercept (Eylea) for the treatment of patients with DR. Ranibizumab (Lucentis) (Genentech/Novartis) 0.3 mg is also approved by the FDA for the monthly treatment of all forms of DR. Intravitreal therapies with anti-VEGF agents, particularly Eylea, and Lucentis have substantially improved the prognosis of potentially severe ocular diseases.
Diabetic Retinopathy key Players
Diabetic Retinopathy Drugs
Diabetic Retinopathy Symptoms
Diabetic retinopathy in initial stages is asymptomatic. However, as diabetic retinopathy gets worse with time, one will notice symptoms such as: seeing an increasing number of floaters, having blurry vision, having a vision that sometimes changes from blurry to clear, seeing blank or dark areas in your field of vision, having poor night vision, and noticing colors appear faded or washed out, losing vision.
Diabetic Retinopathy Pathogenesis
The key pathways involved in the pathogenesis of DR include increased glucose flux through the polyol and hexosamine pathways, activetion of protein kinase C (PKC), overactivation of the plasma kallikrein-kinin (PKK) pathway and accumulation of advanced glycation end products (AGEs). Oxidative stress occurs as a result of hyperglycemia-induced mitochondrial overproduction of superoxide and has been postulated as the underlying stressor linking. Retinal microglia’s morphology changes during diabetes.
Diabetic Retinopathy Market Report
Epidemiological, clinical, and laboratory studies have increased the understanding of the pathophysiological changes of diabetic retinopathy, culminating recently in new treatment options for diabetic macular edema. Furthermore, screening programs have enabled early diagnosis and prompt treatment of sight-threatening retinopathy. Despite these advances in the field, the prevalence of diabetic retinopathy remains high at 40%. Globally, there are approximately 93 million people with diabetic retinopathy, 17 million with proliferative retinopathy, 21 million with diabetic macular edema, and 28 million with sight-threatening retinopathy, making diabetic retinopathy a significant global public health and economic problem.
Diabetic Retinopathy Market Insights
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which is a leading cause of visual loss in working-age populations. The diagnosis of DR is made by clinical manifestations of vascular abnormalities in the retina. DR is, clinically, divided into two stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR represents the early stage of DR, wherein increased vascular permeability and capillary occlusion are two main observations in the retinal vasculature.
Diabetic Retinopathy Treatment
For diabetic retinopathy that is threatening or affecting the patient’s sight, the main treatments are: laser treatment – to treat the growth of new blood vessels at the back of the eye (retina) in cases of proliferative diabetic retinopathy, and to stabilize some cases of maculopathy, eye injections – to treat severe maculopathy ‘’that is threatening your sight, eye surgery – to remove blood or scar tissue from the eye if laser treatment is not possible because retinopathy is too advanced.
Diabetic Retinopathy Market Report Highlights
Get a free sample copy of the basic structure of the report– https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
Table of content
Diabetic Retinopathy Market: Report Key Strengths
Diabetic Retinopathy Market: Report Assessment
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Shruti Thakur
[email protected]
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/